Improving Patient Lives with Single Cell Precision
HiFiBiO is a clinical-stage global biotech pioneering a unique
high-resolution translational solution (DIS®) to enhance
the probability of success
for immunotherapies
Home
Latest News
Apr 7, 2023
HiFiBiO Therapeutics Announces Oral Presentation at 2023 American Association for Cancer Research (AACR) Annual Meeting
CAMBRIDGE, MA – April 7, 2023 – HiFiBiO Therapeutics, a clinical-stage multinational biotherapeutics company, announced today that its scientific work in exploring approaches to target the TIGIT/CD226 axis has been selected for oral presentation at the AACR 2023 meeting during April 14-19, 2023, in Orlando, FL. “To date, the industry has struggled to successfully develop … Continued
Mar 6, 2023
Going Global: Insights on the Advantages of Biotech Globalization Published in Drug Discovery Today from HiFiBiO Therapeutics
Global vs. Local: The Future of Biotech CAMBRIDGE, MA., – March 6, 2023 – HiFiBiO Therapeutics CEO Liang Schweizer and Senior Director Vincent Tse share their thoughts on the advantages of early globalization for biotech startups and provide an operational framework for maximizing the probability of success and societal impact. “In light of the ongoing … Continued
Jan 6, 2023
HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200603
HFB200603 is a novel anti-BTLA Antibody for the treatment of DIS® Defined Solid Tumors CAMBRIDGE, MA.– January 6, 2023 – HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, announced today the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for HFB200603. HFB200603 is a novel monoclonal antibody against the … Continued
Apr 7, 2023
HiFiBiO Therapeutics Announces Oral Presentation at 2023 American Association for Cancer Research (AACR) Annual Meeting
CAMBRIDGE, MA – April 7, 2023 – HiFiBiO Therapeutics, a clinical-stage multinational biotherapeutics company, announced today that its scientific work in exploring approaches to target the TIGIT/CD226 axis has been selected for oral presentation at the AACR 2023 meeting during April 14-19, 2023, in Orlando, FL. “To date, the industry has struggled to successfully develop … Continued
Unprecedented Discovery and Development Engine
Uniqueness
HiFiBiO single-cell focused approach identifies translationally relevant targets, enables rapid drug development, and matches treatments to patients for better clinical outcomes
Learn More
Innovation
DIS® combines unique single-cell capabilities with AI/ML approaches using patient samples to discover novel targets, effective antibody drugs, and predictive biomarkers
Learn More
Impact
DIS® addresses current limitations in drug discovery by linking translationally relevant targets and immunotherapies with the right patient populations to accelerate drug development and increase clinical probability of success
Learn More